Modes of action of Leishmanicidal antimicrobial peptides

Alexandra K. Marr, Bradford S. McGwire, W. Robert McMaster

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Leishmaniasis is one of the major neglected tropical diseases of the world. It is present in 88 countries with an estimated number of 500,000 cases of visceral leishmaniasis and 1.5 million cases of cutaneous disease. No effective vaccinations are available against leishmaniasis and the efficacy of existing treatments is compromised due to the emergence of drug resistance. Thus, there is an urgent need to develop new compounds with antileishmanial activity. Antimicrobial peptides have potential as novel antileishmanial therapy, either for use alone or in combination with current drug regimens. The modes of action of these peptides against Leishmania includes: membrane disruption leading to necrotic cell death; induction of apoptosis; binding to intracellular target(s); and indirect effects via immunomodulation of host immune cells. This article reviews the mechanisms of action of antimicrobial peptides with leishmanicidal activity.

Original languageEnglish
Pages (from-to)1047-1059
Number of pages13
JournalFuture Microbiology
Volume7
Issue number9
DOIs
Publication statusPublished - Sep 2012
Externally publishedYes

Fingerprint

Leishmaniasis
Peptides
Neglected Diseases
Visceral Leishmaniasis
Immunomodulation
Leishmania
Skin Diseases
Drug Resistance
Vaccination
Cell Death
Apoptosis
Membranes
Pharmaceutical Preparations
Therapeutics

Keywords

  • antimicrobial peptide
  • apoptosis
  • immunomodulation
  • Leishmaniasis
  • membrane disruption

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

Modes of action of Leishmanicidal antimicrobial peptides. / Marr, Alexandra K.; McGwire, Bradford S.; McMaster, W. Robert.

In: Future Microbiology, Vol. 7, No. 9, 09.2012, p. 1047-1059.

Research output: Contribution to journalReview article

Marr, Alexandra K. ; McGwire, Bradford S. ; McMaster, W. Robert. / Modes of action of Leishmanicidal antimicrobial peptides. In: Future Microbiology. 2012 ; Vol. 7, No. 9. pp. 1047-1059.
@article{46c39e7b7b9f43bf99c377ee6580482b,
title = "Modes of action of Leishmanicidal antimicrobial peptides",
abstract = "Leishmaniasis is one of the major neglected tropical diseases of the world. It is present in 88 countries with an estimated number of 500,000 cases of visceral leishmaniasis and 1.5 million cases of cutaneous disease. No effective vaccinations are available against leishmaniasis and the efficacy of existing treatments is compromised due to the emergence of drug resistance. Thus, there is an urgent need to develop new compounds with antileishmanial activity. Antimicrobial peptides have potential as novel antileishmanial therapy, either for use alone or in combination with current drug regimens. The modes of action of these peptides against Leishmania includes: membrane disruption leading to necrotic cell death; induction of apoptosis; binding to intracellular target(s); and indirect effects via immunomodulation of host immune cells. This article reviews the mechanisms of action of antimicrobial peptides with leishmanicidal activity.",
keywords = "antimicrobial peptide, apoptosis, immunomodulation, Leishmaniasis, membrane disruption",
author = "Marr, {Alexandra K.} and McGwire, {Bradford S.} and McMaster, {W. Robert}",
year = "2012",
month = "9",
doi = "10.2217/fmb.12.85",
language = "English",
volume = "7",
pages = "1047--1059",
journal = "Future Microbiology",
issn = "1746-0913",
publisher = "Future Medicine Ltd.",
number = "9",

}

TY - JOUR

T1 - Modes of action of Leishmanicidal antimicrobial peptides

AU - Marr, Alexandra K.

AU - McGwire, Bradford S.

AU - McMaster, W. Robert

PY - 2012/9

Y1 - 2012/9

N2 - Leishmaniasis is one of the major neglected tropical diseases of the world. It is present in 88 countries with an estimated number of 500,000 cases of visceral leishmaniasis and 1.5 million cases of cutaneous disease. No effective vaccinations are available against leishmaniasis and the efficacy of existing treatments is compromised due to the emergence of drug resistance. Thus, there is an urgent need to develop new compounds with antileishmanial activity. Antimicrobial peptides have potential as novel antileishmanial therapy, either for use alone or in combination with current drug regimens. The modes of action of these peptides against Leishmania includes: membrane disruption leading to necrotic cell death; induction of apoptosis; binding to intracellular target(s); and indirect effects via immunomodulation of host immune cells. This article reviews the mechanisms of action of antimicrobial peptides with leishmanicidal activity.

AB - Leishmaniasis is one of the major neglected tropical diseases of the world. It is present in 88 countries with an estimated number of 500,000 cases of visceral leishmaniasis and 1.5 million cases of cutaneous disease. No effective vaccinations are available against leishmaniasis and the efficacy of existing treatments is compromised due to the emergence of drug resistance. Thus, there is an urgent need to develop new compounds with antileishmanial activity. Antimicrobial peptides have potential as novel antileishmanial therapy, either for use alone or in combination with current drug regimens. The modes of action of these peptides against Leishmania includes: membrane disruption leading to necrotic cell death; induction of apoptosis; binding to intracellular target(s); and indirect effects via immunomodulation of host immune cells. This article reviews the mechanisms of action of antimicrobial peptides with leishmanicidal activity.

KW - antimicrobial peptide

KW - apoptosis

KW - immunomodulation

KW - Leishmaniasis

KW - membrane disruption

UR - http://www.scopus.com/inward/record.url?scp=84866123666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866123666&partnerID=8YFLogxK

U2 - 10.2217/fmb.12.85

DO - 10.2217/fmb.12.85

M3 - Review article

VL - 7

SP - 1047

EP - 1059

JO - Future Microbiology

JF - Future Microbiology

SN - 1746-0913

IS - 9

ER -